Dianthus Therapeutics (DNTH) EBIT (2017 - 2025)
Dianthus Therapeutics' quarterly EBIT came in at -$40.3 million in Q3 2025, down 34.74% year-on-year from -$61.7 million in Q3 2024, and down 15.35% quarter-over-quarter from -$34.9 million in Q2 2025.
Dianthus Therapeutics has reported EBIT for 9 years, with the latest figure at -$40.3 million in Q3 2025.
- For the quarter ending Q3 2025, EBIT fell 34.74% year-over-year to -$40.3 million; the trailing twelve-month figure through Sep 2025 stood at -$140.3 million (down 69.24% YoY), and the FY2024 full-year result was -$101.9 million, down 111.45% from the prior year.
- EBIT for Q3 2025 stood at -$40.3 million, down from -$34.9 million in the prior quarter.
- The five-year high for EBIT was -$7.7 million in Q1 2023, with the low at -$40.3 million in Q3 2025.
- Average EBIT over 5 years is -$20.7 million, with a median of -$18.2 million recorded in 2021.
- Year-over-year, EBIT soared 67.76% in 2023 and sank 146.34% in 2024.
- Tracing DNTH's EBIT over 5 years: stood at -$20.1 million in 2021, then jumped by 46.91% to -$10.7 million in 2022, then decreased by 21.16% to -$13.0 million in 2023, then slumped by 146.34% to -$31.9 million in 2024, then declined by 26.23% to -$40.3 million in 2025.
- The last three EBIT figures came in at -$40.3 million (Q3 2025), -$34.9 million (Q2 2025), and -$33.2 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Dianthus Therapeutics | 4.02 Bn | 3.62 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -40.29 Mn |
| Jun 30, 2025 | -34.93 Mn |
| Mar 31, 2025 | -33.18 Mn |
| Dec 31, 2024 | -31.92 Mn |
| Sep 30, 2024 | -29.90 Mn |
| Jun 30, 2024 | -22.20 Mn |
| Mar 31, 2024 | -17.84 Mn |
| Dec 31, 2023 | -12.96 Mn |
| Sep 30, 2023 | -15.76 Mn |
| Jun 30, 2023 | -11.78 Mn |
| Mar 31, 2023 | -7.68 Mn |
| Dec 31, 2022 | -10.69 Mn |
| Sep 30, 2022 | -8.25 Mn |
| Jun 30, 2022 | -18.08 Mn |
| Mar 31, 2022 | -23.83 Mn |
| Dec 31, 2021 | -20.14 Mn |
| Sep 30, 2021 | -18.25 Mn |
| Jun 30, 2021 | -17.61 Mn |
| Mar 31, 2021 | -18.70 Mn |
| Dec 31, 2020 | -19.07 Mn |
| Sep 30, 2020 | -18.38 Mn |
| Jun 30, 2020 | -20.01 Mn |
| Mar 31, 2020 | -21.24 Mn |
| Dec 31, 2019 | -24.64 Mn |
| Sep 30, 2019 | -22.64 Mn |
| Jun 30, 2019 | -19.34 Mn |
| Mar 31, 2019 | -16.35 Mn |
| Dec 31, 2018 | -17.93 Mn |
| Sep 30, 2018 | -16.70 Mn |
| Jun 30, 2018 | -14.03 Mn |
| Mar 31, 2018 | -11.31 Mn |
| Dec 31, 2017 | -8.17 Mn |
| Sep 30, 2017 | -7.02 Mn |
| Jun 30, 2017 | -15.73 Mn |